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Available online 11 October 2016Background: Patients undergoing elective electrical cardioversion (ECV) for atrial ﬁbrillation have a temporarily
increased risk of thromboembolism. Current guidelines recommend adequate anticoagulation for ≥3 consecutive
weeks precardioversion, i.e. consecutive INR values 2.0–3.0 in patients with vitamin K antagonists (VKA). We
aimed to evaluate the occurrence and impact of subtherapeutic INRs precardioversion and to study factors
associated with these unwanted ﬂuctuations.
Methods:We recruited 346 consecutive patients undergoing elective ECV in the Maastricht University Medical
Centre between 2008 and 2013. Predictors of subtherapeutic INR values were identiﬁed and incorporated into
a logistic regression model.
Results: A subtherapeutic INR precardioversion occurred in 55.2% of patients. The only statistically signiﬁcant
predictor was VKA-naivety (Odds Ratio (OR) 4.78, 95% Conﬁdence Interval (CI) 2.67–8.58, p b 0.001). In patients
with ≥1 subtherapeutic INR precardioversion, time from referral until cardioversion was 91.1 ± 42.8 days,
compared to 41.7 ± 26.6 days (p b 0.001) in patients without subtherapeutic INRs.
No thromboembolic events occurred b30 days after the ECV. Independent predictors for the combined endpoint
of cardiovascular death, ischemic stroke and the need of blood transfusion (n = 30, median follow-up of
374 days) were coronary artery disease in the history (OR 3.35, 95%CI 1.54–7.25, p= 0.002) and subtherapeutic
INR precardioversion (OR 3.64, 95%CI 1.43–9.24, p = 0.007).
Conclusions: The use of VKA often results in subtherapeutic INRs precardioversion and is associated with a
signiﬁcant delay until cardioversion, especially in patients with recent initiation of VKA therapy. Furthermore,
subtherapeutic INR levels prior to ECV are associated with the combined endpoint of cardiovascular death,
ischemic stroke and the need of blood transfusion.






Atrial ﬁbrillation (AF) is the most common sustained cardiac
arrhythmia. It is a major health problem, not merely due to its vastness
but also because of the associated risks, in particular of thromboembo-
lism (TE). Besides the intrinsic TE risk, there is an independent, transient
risk of TE in AF patients in case of cardioversion. Of note, all types of
cardioversion — i.e. spontaneous, pharmacological and electrical —
carry a similar TE risk [1,2]., Maastricht University Medical
s.
land Ltd. This is an open access articlThe temporarily increased TE risk pericardioversion is mainly
believed to be caused by stasis of blood in theﬁbrillating atria, especially
in the left atrial appendage. Even following restoration of sinus rhythm,
mechanical dysfunction of the atria — so-called atrial stunning — may
persist, thereby prolonging the temporary increased TE risk [3]. Thus,
pericardioversion oral anticoagulation is warranted to signiﬁcantly
decrease the rate of thromboembolic complications from 5.3% to 0.8–
1.0% [4,5].
Current international guidelines recommend adequate anti-
coagulation for at least threeweeks prior, and four weeks following car-
dioversion in patients with AF of N48 h or of unknown duration [6].
When using vitamin K antagonists (VKA), this means achieving and
maintaining an INR between 2.0 and 3.0 during the above deﬁned
pericardioversion window. However, the well-known VKA hurdlese under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Planned cardioversions (n = 386) 
CV cancelled (n = 40)
- Spontaneous SR (n = 36) 
- Cancelled by physician (n = 3) 
- Paroxysmal AF (n = 1) 
CV postponed (n = 29)
- Low INR (n=24) 
- High INR (n = 2) 
- Hyperkalemia (n = 2) 
- Hypokalemia (n = 1) 
Performed cardioversions (n = 346) 
Fig. 1. Study ﬂow chart.
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levels [7,8] and proof particularly challenging during initiation [9].
Importantly, sub- and supratherapeutic levels are clearly related to
increasedmortality and serious adverse outcomes, such as thromboem-
bolism and major bleeding [8,10].
Furthermore, inadequate anticoagulation management can also
cause a time delay to cardioversion [11–13] and thereby postpone
alleviating AF related symptoms, which is usually the primary goal of
cardioversion [14]. Whether the same delay has a signiﬁcant effect on
the total AF duration and consequent success of conversion to, and
long-term maintenance of, sinus rhythm — explained by structural
and electrical remodeling [11]— remains debatable [15–17].
The objective of this study is to evaluate the occurrence, extent and
impact of subtherapeutic INR values prior to and following elective




We recruited consecutive unique patients with atrial ﬁbrillation and ﬂutter
undergoing elective, direct current cardioversions between December 2008 and
February 2013 in the Maastricht University Medical Centre in the Netherlands using the
prospective Maastricht Cardioversion Registry. Ethical approval for the registry was
obtained from the Institutional Review Board. Patients were eligible for inclusion given
an age ≥18 years and persistent AF or atrial ﬂutter conﬁrmed by a 12-lead electrocardio-
gram (ECG). Exclusion criteria were AF duration b48 h or the need for urgent cardiover-
sion because of hemodynamic instability.
Patients already using VKA were scheduled for weekly INR measurements and VKA-
naive patients were prescribed acenocoumarol and referred to local Thrombosis Services.
Our hospitals elective cardioversion protocol is in linewith the international guidelines on
AF recommending threeweeks of adequate anticoagulation (INR 2.0–3.0) prior to and four
weeks following cardioversion. We deﬁned subtherapeutic anticoagulation as any
INR b 2.0 from the moment the patient was referred for cardioversion.
On the scheduled day of cardioversion, a 12-lead ECG was performed to determine
heart rhythm and a venous blood sample was drawn to determine INR and potassium
levels. In case of an INR b 2.0 or signiﬁcant potassium disturbances, cardioversion was
postponed. In case of spontaneous conversion to sinus rhythm, cardioversion was
canceled.
All cardioversions were carried out according to protocol. Cardioversion was
performed by a cardiology resident using a biphasic waveform deﬁbrillator (Medtronic
LIFEPAK® Physio-Control 20) with anterolateral paddle position. Antero-posterior
position could be preferred or necessary in selected patients, i.e. in patients with cardiac
implantable electronic devices. In case of unsuccessful deﬁbrillation, increasing energy
levels were applied with a maximum of three attempts to restore sinus rhythm (200–
300–360 J). Propofol or etomidate was used for sedation at the discretion of the
anesthesiologist.
Cardioversion was considered successful upon sinus rhythm restoration and
maintenance until discharge the same day. A standard follow-up outpatient clinic visit
was planned one month following discharge or earlier if deemed clinically necessary.
Follow-up was performed until June 2013.
2.2. Data analysis
Baseline demographics, medical history, medication use, echocardiographic ﬁndings
and speciﬁc information about anticoagulation management were obtained from our
digital hospital records. Sinus rhythm maintenance was evaluated during follow-up on
the basis of all available 12 lead ECGs from the routine follow-up outpatient clinic visits.
The occurrence of ischemic or hemorrhagic stroke was also assessed by reviewing the
digital hospital records. Clinically relevant bleeding events were retrieved by identifying
patients who needed blood transfusion.
During the course of this study, the target range for INRs in AF patients was 2.5–3.5 in
the Netherlands, as recommended at that time by the Federation of Dutch Thrombosis
Services. However, given the minimum INR value of 2.0 to safely perform a cardioversion,
we only considered an INR b 2.0 as subtherapeutic. We reviewed all INR measurements
between referral and performance of cardioversion. To evaluate a possible delay we
calculated the time between referral and the actual cardioversion.
2.3. Statistical analysis
Datawere analyzed using SPSS 22.0 (SPSS Inc., Chicago, IL, USA). Continuous variables
are reported as mean ± standard deviation or median (25–75% quartiles) and categorical
variables as number of observed patients (percentage). Chi square test was used for com-
parison of categorical variables between groups. Fisher's exact test was used if any expect-
ed cell count was b5. Normally distributed continuous variables were compared between
two groups using the independent samples t-test, whereas not normally distributedcontinuous variables were compared using the Mann–Whitney U test. The distribution
of continuous variables was visually checked for normality.
Predictors of subtherapeutic INR values were identiﬁed by incorporating all baseline
characteristics with a signiﬁcant univariate relationship and biologically plausible
variables into a logistic regression model, with stepwise reduction of the model for
variables with a p value b0.1. All variables in the ﬁnal model with a p value b0.05 were
considered signiﬁcant independent predictors and were tested for interactions.
3. Results
A total of 386 patients were planned to undergo an elective ECV
between 2008 and 2013. Of these, 40 (10.4%) were canceled and 29
(7.5%) were postponed on the day of cardioversion and performed
later (see breakdown Fig. 1). Baseline rhythm before cardioversion
was atrial ﬁbrillation in 90% and atrial ﬂutter in 10% of the patients. An
antero-lateral paddle position was used in 92.5% of cardioversions.
One shock was sufﬁcient to restore sinus rhythm in 76% with a total
success rate of electrical cardioversion of 90%.
3.1. Anticoagulation management before cardioversion
At least one subtherapeutic INR prior to the cardioversion occurred
in 191 of 346 patients (55.2%), with an average of 2.8 ± 2.3 subthera-
peutic INR values. The baseline characteristics of these patients and
their adequately anticoagulated counterparts are displayed in Table 1.
In 23.7% of the patients with inadequate anticoagulation management,
the subtherapeutic INR was preceded by a supratherapeutic INR
(N3.5). In addition, despite adequate anticoagulation prior to the
cardioversion, 29 cardioversions (8.4%)were postponed on the planned
day of cardioversion due to a subtherapeutic INR value and were
performed later (Fig. 1). The time in therapeutic range (TTR) in the
time period between referral and performing of cardioversion was
0.79 ± 0.12 in the patients with subtherapeutic INRs.
Possible predictors for subtherapeutic INR values precardioversion
were assessed using logistic regression. After stepwise reduction of
the model, the only remaining statistically signiﬁcant predictor was
VKA-naivety (Odds Ratio (OR) 4.78, 95% Conﬁdence Interval (CI)









Age at ECV 66.9 ± 10.5 68.0 ± 10.2 0.336
Age at ﬁrst presentation AFb 65.6 ± 11.0 64.9 ± 11.8 0.598
Female sex 60 (31.4%) 55 (35.5%) 0.424
CHA2DS2-VASc
0 15 (7.9%) 13 (8.4%) 0.694
1 44 (23.0%) 25 (16.1%) 0.079
2 39 (20.4%) 40 (25.8%) 0.181
3 41 (21.5%) 31 (20.0%) 0.715
4 22 (11.5%) 26 (16.8%) 0.086
5 19 (9.9%) 15 (9.7%) 0.582
6 9 (4.7%) 4 (2.6%) 0.300
7 2 (1.0%) 1 (0.6%) 0.688
8–9 0 0
Body mass index 28.9 ± 5.3 (n = 176) 28.8 ± 5.1 (n = 145) 0.822
Patient history
Hypertension 108 (56.5%) 85 (54.8%) 0.751
Heart failure 43 (22.5%) 32 (20.6%) 0.675
Type II diabetes 33 (17.3%) 16 (10.3%) 0.065
Coronary artery disease 60 (31.4%) 47 (30.3%) 0.827
Ischemic CVA 6 (3.1%) 7 (4.5%) 0.504
Hemorrhagic CVA 0 (0%) 1 (0.6%) 0.448
TIA 9 (4.7%) 11 (7.1%) 0.345
Hypercholesterolemia 41 (21.5%) 23 (14.8%) 0.114
Peripheral thromboembolism 6 (3.1%) 0 0.035⁎
COPD 12 (6.3%) 9 (5.8%) 0.854
OSAS 8 (4.2%) 6 (3.9%) 0.882
Echocardiography at baseline
LVEF 47.6 ± 12.4 (n = 188) 51.2 ± 12.0 (n = 151) 0.007⁎
LA dimension, mm 45.5 ± 6.6 (n = 183) 45.9 ± 6.4 (n = 144) 0.575
Medication at baseline
VKA-naivety 70 (37.2%, n = 188) 17 (11.0%, n = 154) b0.001⁎
Acetylsalicylic acid 2 (1.0%) 3 (1.9%) 0.660
AAD
Amiodarone 22 (11.5%) 28 (18.1%) 0.085
Sotalol 12 (6.3%) 14 (9.0%) 0.335
Flecainide 3 (1.6%) 7 (4.5%) 0.119
Beta blockerc 159 (83.2%) 119 (76.8%) 0.132
Digitalis 54 (28.3%) 42 (27.1%) 0.808
Verapamil/diltiazem 10 (5.2%) 15 (9.7%) 0.113
Isosorbide mononitrate 25 (13.1%) 20 (12.9%) 0.959
ACE-inhibitor 74 (38.7%) 56 (36.1%) 0.618
ATII receptor antagonist 61 (31.9%) 49 (31.6%) 0.949
Diuretic 92 (48.2%) 72 (46.5%) 0.751
Dihydropyridine 29 (15.2%) 19 (12.3%) 0.434
Statin 79 (41.4%) 75 (48.4%) 0.191
Abbreviations: AAD= anti-arrhythmic drugs, ACE= angiotensin converting enzyme, AF= atrial ﬁbrillation, ATII = angiotensin II, CVA= cerebrovascular accident, COPD= chronic ob-
structive pulmonary disease, ECV= electrical cardioversion, LA= left atrium, LVEF= left ventricular ejection fraction, OSAS= obstructive sleep apnea syndrome, TIA= transient ische-
mic attack, VKA = vitamin K antagonist.
a Data are presented as means ± standard deviation or no. (%). N = 191 or 155, unless otherwise speciﬁed.
b Conﬁrmed by ECG recording.
c Sotalol excluded.
⁎ Statistically signiﬁcant, p b 0.05.
Fig. 2.Mean time from referral to cardioversion for patients subdivided by the number of
subtherapeutic INRs (right y-axis) and the sample size per group (left y-axis).
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time from referral until cardioversion was 91.1 ± 42.8 days, compared
to 41.7 ± 26.6 days (p b 0.001) in patients without a subtherapeutic
INR value before cardioversion. The relationship between the number
of subtherapeutic INRs and the time to cardioversion is depicted in
Fig. 2. In VKA naive patients, time from referral until cardioversion
was 84.5 ± 40.6 days, compared to 63.6 ± 44.0 days (p b 0.001) in pa-
tients already on vitamin K antagonists before referral to cardioversion.
3.2. Anticoagulation management postcardioversion
INR measurements 1, 2, 3, and 4 weeks after cardioversion could be
retrieved in 87.9%, 85.5%, 72.8% and 37.0% of the patients, respectively. A
subtherapeutic INR was found in 11.5%, 11.1%, 11.1% and 12.5% of these
patients. In total, 30.0% of patients with available follow-up on INR
340 Ö. Erküner et al. / International Journal of Cardiology 225 (2016) 337–341values postcardioversion showed at least one subtherapeutic INR.
Possible predictors for subtherapeutic INR values postcardioversion
were assessed using logistic regression in a similar manner to the
analysis of precardioversion subtherapeutic INRs. However, no statisti-
cally signiﬁcant predictors could be identiﬁed.
3.3. Mortality, strokes and events requiring blood transfusion during
follow-up
The median follow-up was 374 days (147–818 days), 31 patients
(9.0%) were lost to follow-up. A total of 20 patients died during
follow-up, of whom5 died of cardiovascular causes. One death occurred
4 days after cardioversion. This patient lived alone and was found dead
at home by her family. Autopsy showed severe coronary artery disease
and myocarditis. Cerebral autopsy showed no signs of ischemic stroke,
thus a direct relationship with the cardioversion could not be
established. No other deaths occurred within 30 days after the
cardioversion.
Ischemic stroke occurred in 5 patients (1.5%) during follow-up. None
of the strokes occurredwithin 30days following cardioversion (range of
204–1658 days). Thus, no direct relationship with the cardioversion
could be established.
No hemorrhagic strokes occurred during follow-up. A total of 22
patients received blood transfusion postcardioversion. None of these
occurredwithin 30 days after cardioversion.Median time to transfusion
was 420 days (139–762 days).
For the combined endpoint of cardiovascular death, ischemic stroke
and the need of blood transfusion (n = 30), statistically signiﬁcant
predictors were subtherapeutic INR values prior to ECV (OR 3.64,
95%CI 1.43–9.24, p = 0.007) and coronary artery disease in the history
(OR 3.35, 95%CI 1.54–7.25, p = 0.002).
4. Discussion
In this cohort of patients undergoing elective electrical cardioversion
we observed that subtherapeutic INR levels prior to cardioversion
occurred frequently (55.2%) and were associated with a signiﬁcant
prolongation of the time from referral until cardioversion (91 vs.
42 days, p b 0.001). In nearly a quarter of these patients, the subthera-
peutic INR value was preceded by a supratherapeutic INR value
(N3.5). This implies that VKA dose adjustments should be made with
precaution in patients on the waiting list for elective cardioversion,
since one subtherapeutic INR value means a delay of cardioversion of
at least 4 weeks.
Recent initiation of VKA was associated with inadequate INRs
precardioversion. Time to cardioversion for VKA-naive patients was on
average 85 days, compared to 64 days for patients already on VKA.
This difference is probably accountable to the initial ﬂuctuation of
INRs after starting with VKA therapy and the time needed to acquire
stable and adequate INR values.
Despite adequate anticoagulation management prior to the cardio-
version, a substantial amount of patients (8.4%) had a subtherapeutic
INR value on the day they were planned to undergo the cardioversion.
This not only means that the patient has to wait for an additional
4 weeks at best, but also impedes reduction of the waiting list since
another patient could have undergone the ECV on that day. This could
partly explain the fact that the mean time to cardioversion in the
group with adequate anticoagulation management prior to the
cardioversion is 42 days, which is still much longer than the required
21 days according to the guidelines [6].
After cardioversion, we observed at least one subtherapeutic INR
value in 30% of the patients with known anticoagulation follow-up. No
thromboembolic events occurred within 30 days of the ECV, whereas
we would have expected 4 events based on a prevalence of 0.8–1.0%
[5]. Furthermore, no major bleedings occurred within 30 days of
cardioversion.Factors associated with the combined endpoint of cardiovascular
death, ischemic stroke and the need of blood transfusion were
subtherapeutic INRs prior to cardioversion and a history of coronary
artery disease (CAD). CAD likely acts as a general marker of vascular
weakness, resulting in both thromboembolism and bleeding events.
Inadequate anticoagulation management prior to the cardioversion
could be a marker of long term cardiovascular events, but could also
be the underlying mechanism of these events via chronically subopti-
mal anticoagulation management. This is in line with a previous report
showing that time in therapeutic range (TTR) in the initial phase after
starting VKA therapy is highly predictive for the long term TTR [18].
Furthermore, subtherapeutic INRs precardioversion are comparable to
“labile INR” as used in the bleeding risk score HAS-BLED (Hypertension,
Abnormal renal/liver function, Stroke, Bleeding history or predisposi-
tion, Labile INR, Elderly (N65 years), Drugs/alcohol concomitantly)
[19]. Patients with subtherapeutic INRs prior to cardioversion could
therefore be seen as the patients who have a higher risk of developing
bleeding events on the long run due to frequently occurring
supratherapeutic INRs. Switching to a non-VKA oral anticoagulant
drug (NOAC) could be beneﬁcial in these patients by eliminating a
ﬂuctuating anticoagulation level, not only leading to a reduced access
time for elective cardioversion but also possibly leading to less bleeding
events by eliminating supratherapeutic INRs.
At the time of inclusion and follow-up of this study, the INR range
used by the Federation of Dutch Thrombosis Services for patients with
AF was higher than the international recommendations (2.5–3.5 vs.
2.0–3.0). This would in theory translate into a smaller number of sub-
therapeutic INR levels and subsequent postponement since there is a
buffer for the occurrence of subtherapeutic INRs. Also meaning that
the prevalence of subtherapeutic INRs can be higher than reported in
this study in countries using the internationally recommended INR
range. As of January 1st 2016, the INR target range in the Netherlands
has been changed and is now the same as used internationally. This
could mean that subtherapeutic INR values precardioversion will be
more prevalent in the Netherlands from now on when compared to
the results found in this study.
Our study highlights the struggles of achieving adequate
anticoagulation with VKA in patients undergoing an ECV. The
ﬂuctuations in the level of anticoagulation, expressed in INR values,
substantially affects the time to cardioversion. However, in our study,
no adverse effects on patient outcomes were observed.
NOACs appear to be good alternatives to VKAs in patients planned
for ECV, especially for thosewho are more likely to have subtherapeutic
INR values, i.e. patients who have not yet started an anticoagulant drug.
Both dabigatran and rivaroxaban have proven to be non-inferior to VKA
treatment regarding safety endpoints in patients undergoing electrical
cardioversion [5,20,21]. Additionally, NOACs have the advantage of
not being dependent on a ﬂuctuating anticoagulation level when
taken as prescribed. This advantage can shorten both the time to cardio-
version for the patient and the waiting list for elective cardioversion in
general.4.1. Limitations
Not all patients undergoing elective ECV could be included due to
missing INR data. Furthermore, only clinically relevant major bleedings
were taken into account since minor bleedings could not be uniformly
obtained from the patient ﬁles.
At the time of inclusion and follow-up of this study, the INR range
used by the Federation of Dutch Thrombosis Services was higher
compared to international recommendations. This potentially translates
into an underestimation of the prevalence of subtherapeutic INR values
in countries using the internationally recommended INR range, like the
Netherlands at present, possibly leading to an even longermean time to
cardioversion than reported in this study.
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The use of vitamin K antagonists often results in subtherapeutic INR
levels prior to elective ECV and is associated with a signiﬁcant delay
until cardioversion, especially in patients with recent initiation of VKA
therapy. Furthermore, subtherapeutic INR levels prior to ECV are associ-
ated with the combined endpoint of cardiovascular death, ischemic
stroke and the need of blood transfusion.
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